Description
ALPESIB 150 MG (Alpelisib)
ALPESIB 150 MG is a targeted anti-cancer drug containing alpelisib as the active ingredient. Alpelisib is a selective PI3K inhibitor used to treat some kinds of advanced or metastatic breast cancer. The drug is a film-coated tablet that is aimed to reduce the course of cancer by targeting aberrant molecular pathways involved in tumor growth.
Alpelisib belongs to a pharmacologic family called kinase inhibitors and more precisely to the alpha-specific phosphoinositide 3-kinase (PI3K) inhibitor subclass. The drug is mostly used in combination with hormonal therapy such as Fulvestrant in patients with verified mutation in the PIK3CA gene and hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.
ALPESIB 150 MG is a big leap forward in precision oncology, as it targets tumors generated by genetic anomalies in the PI3K pathway. This targeted therapy is different from the standard chemotherapy since it targets molecular abnormalities that cause cancer cells to grow uncontrollably.
What is Alpelisib?
Alpelisib is a targeted cancer treatment that blocks the PI3K signaling pathway which is often overactive in several malignancies, including breast cancer.
The PI3K pathway is crucial in:
- Cellular Growth
- Cell division
- Survival of cells
- Glucose metabolism
- Tumor progression
In patients with PIK3CA mutations, this pathway is incorrectly turned on, allowing the cancer cells to grow quickly and to resist typical hormone treatments. ALPESIB 150 MG is a selective inhibitor of the alpha isoform of the PI3K enzyme. It helps to stop the proliferation of cancer cells and improves responsiveness to treatment.
Alpelisib is a precision drug created for cancers with known molecular aberrations, due to its unique method of action.
Medical Uses of ALPESIB 150 MG
HR-Positive, HER2-Negative Breast Cancer Treatment
ALPESIB 150 MG is indicated in combination with Fulvestrant for the treatment of:
- HR positive (hormone receptor positive)
- HER2- (negative)
- Advanced or metastatic breast cancer
It is widely used in post-menopausal women and men with progressive cancer following earlier endocrine therapy.
Tumors with PIK3CA mutation
This drug is only for patients whose tumors test positive for PIK3CA mutations. A confirmed diagnosis is usually made with a diagnostic test or biopsy before starting treatment.
PIK3CA mutations are prevalent genetic abnormalities in HR-positive breast cancer and are related with:
- Tumor development
- Resistance to treatment
- Course of disease
ALPESIB 150 MG directly targets this mutation which assists in improving treatment outcomes in qualified individuals.
In combination with Fulvestrant
Fulvestrant is a hormonal treatment that prevents the action of the estrogen receptor. Alpelisib and Fulvestrant in Combination Alpelisib and Fulvestrant combined offer a dual-action therapeutic strategy that addresses both the hormonal and molecular causes of breast cancer.
How ALPESIB 150 MG Works
ALPESIB 150 MG works by blocking the alpha isoform of PI3K enzyme.
PIK3CA mutations are present in most tumors with hyperactivation of the PI3K pathway . When activated inappropriately, this pathway transmits constant signals that promote cancer cells to:
- Increase swiftly
- Stop cells from dying
- Spread to other tissue
- Resistance to endocrine therapy
Alpelisib targets PI3K-alpha activity directly to suppress these signals. This helps break:
- Slow growing tumor
- Decreased cancer cell survival
- Enhance the response to hormone therapy
- Slow down disease progression
The medicine targets only specific cancer-related mutations, rather than all rapidly dividing cells, which is a major difference from typical chemotherapy treatments.
Dosage And Directions For Use
ALPESIB 150 MG must be used only under the guidance of a qualified cancer specialist.
Adult Dosage (Regular)
The beginning dose for the treatment of breast cancer is:
- 300mg once daily
- As two tablets of 150 mg each
Food Needs
Always take the tablets as follows:
- With the food
- At around the same time every day
It is best to take the medication with food to help with optimal absorption and consistent drug levels in the body.
Tablets Handling Instructions
Patients must be:
- Take the pills whole with a liquid
- Never break, split, crush or chew tablets
- Do not use damaged pills.
Improper handling can make drugs less effective or unsafe.
What to Do if You Forget a Dose
If you skip a dose:
- It can still be taken with food within 9 hours of the planned time
- If it is more than 9 hours past the time you missed your dose, omit the missed dose and take your next dose at the regular time.
- Do not take a double dose to make up for a missing dose.
Always carefully follow the recommendations of your health care professional.
ALPESIB 150 MG Benefits
Precision Targeted Therapy
ALPESIB 150 MG has been developed to fight against tumors with mutations in PIK3CA, therefore offering a more precise and stronger treatment.
Non-Chemotherapy Therapeutics
Unlike standard chemotherapy, Alpelisib works by targeting molecular abnormalities instead of all rapidly dividing cells.
Better Combination Therapy
The drug may assist increase progression-free survival in patients with advanced breast cancer when used with Fulvestrant.
Oral Administration
The tablet formulation permits outpatient treatment without the need for intravenous infusion.
Hormone Resistance-Breaking Ability
ALPESIB 150 MG may help to re-sensitize tumors that have stopped responding well to endocrine therapy alone to treatment.
ALPESIB 150 MG Common Side Effects
Like all medicines, ALPESIB 150 MG may produce adverse effects, however these don’t happen in everyone. Some reactions may need medical monitoring and supportive therapy.
Hyperglycemia
One of the most prevalent side effects of Alpelisib is severe elevated blood sugar.
- Symptoms can include:
- Extreme thirst
- Polyuria
- Tiredness
- Blurred eyesight
Patients on therapy may need periodic monitoring of fasting blood glucose.
Rash Skin
Maculopapular rash and other cutaneous responses are relatively common and may range from moderate to severe.
Gastrointestinal Issues
Digestive side effects can include:
- Diarrhoea
- Nauseous.
- Throwing up
- Anorexia nervosa
- Weight reduction
If left untreated, severe diarrhea can cause dehydration.
Mouth ulcers (stomatitis)
You may have mouth sores or inflammation inside your mouth during therapy.
Tiredness
Some people may feel weak, fatigued or have no energy during treatment.
Important Warnings and Precautions
Blood Glucose Testing
PI3K suppression can influence glucose metabolism. Close monitoring for hyperglycemia is required, especially in patients with diabetes or pre-diabetes.
Serious Skin Reactions
Patients should report immediately:
- Burning
- Skin peeling
- Serious rash
- Skin irritation (painful)
Dehydration and Diarrhea
Chronic diarrhea can lead to dehydration and electrolyte abnormalities which may require medical treatment.
Pregnancy and Lactation
ALPESIB 150 MG may harm the unborn infant. During treatment effective contraception should be used.
Breastfeeding is not usually recommended while you are being treated with this medicine.
Monitoring of Liver Function
Liver function tests may need to be done regularly while being treated.
Interactions with drugs
ALPESIB 150 MG may interact with other drugs and supplements.
Patients should inform their health care provider about all:
- Medicines by prescription
- Over the counter medications
- Vitamin.
- Phytotherapeutics
Caution is especially warranted for drugs affecting liver enzyme activity.
How to Keep
To achieve efficacy and stability:
- Store at less than 25°C
- Store in a cool, dry area
- Store in a cool, dry place, protected from sunshine
- Keep out of the reach of youngsters.
- Do not take expired medication
Summary
ALPESIB 150 MG is a new targeted medication for patients with HR-positive, HER2-negative advanced or metastatic breast cancer who have PIK3CA mutations. Alpelisib specifically targets the PI3K-alpha pathway, slowing the growth of cancer and enhancing the response to treatment when used in combination with hormonal therapies such as Fulvestrant.
Its highly selective mode of action offers an important treatment alternative for people with cancer that has progressed following hormone therapy. The drug is effective in therapy, but requires monitoring because of possible side effects such as hyperglycaemia, skin responses and gastrointestinal issues.
ALPESIB 150 MG should be taken only on a doctor’s prescription. Regular monitoring and adherence to the authorized course of therapy are essential to achieve safe and effective results.
